Laura Panjwani

Articles

Expert Says Radium-223 Emerged as “Surprise” Solution to Improving OS in mCRPC

March 22nd 2016

E. David Crawford, MD, discusses the history of radium-223 dichloride (Xofigo) and how it could be used in the future.

Mittendorf Explains Growing Role of Checkpoint Inhibitors in Breast Cancer

March 21st 2016

Elizabeth Mittendorf, MD, PhD, discusses checkpoint inhibition studies in triple-negative breast cancer, potential ways to make other subtypes more immunogenic to improve response, the role of PD-1, and what’s next in the field of immunotherapy in breast cancer.

Frontline Therapy Rapidly Evolving for Multiple Myeloma

March 18th 2016

Shaji Kumar, MD, discusses how the phase III SWOG S0777 study, which investigated the combination of bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone, significantly changed the frontline treatment paradigm for patients with multiple myeloma

Beyond PSA: What's Next for Prostate Cancer Detection?

March 17th 2016

Stacy Loeb, MD, discusses how screening tests for prostate cancer work, what their benefits are, and what urological specialists need to know in order to best utilize them.

Expert on PD-L1/CTLA-4 Blockade and Future of Immunotherapy in Lung Cancer

March 17th 2016

Scott J. Antonia, MD, discusses how the combination of the PD-L1 inhibitor durvalumab and the CTLA-4 inhibitor tremelimumab, showed antitumor activity in patients with locally advanced or metastatic non–small cell lung cancer, irrespective of PD-L1 status.

New Agents Transform Treatment of Non-Hodgkin Lymphoma

March 16th 2016

Mitchell Smith, MD, discusses advancements in the field of non-Hodgkin lymphoma.

Atezolizumab Approaches FDA Approval in Bladder Cancer, But Biomarkers Remain Unclear

March 15th 2016

Matthew Galsky, MD, explains the challenges of utilizing molecular subtyping and PD-L1 as biomarkers, the impact a potential approval of atezolizumab could have in metastatic bladder cancer, possible combinations that could increase ORR, and next steps in understanding the IMvigor study.

Mittendorf Explains What's New With NeuVax in Breast Cancer

March 14th 2016

Elizabeth A. Mittendorf, MD, PhD, discusses nelipepimut-S (NeuVax), a peptide derived from HER2 protein combined with granulocyte-macrophage colonystimulating factor that is currently being investigated as a single-agent, in combination with standard-of-care therapies, and in multiple settings and subtypes of breast cancer.

Nivolumab Practice-Changing in RCC, But Biomarkers Still Critical for Progress

March 9th 2016

Jorge Garcia, MD, discusses CheckMate-025, the challenges with PD-1 as a biomarker, additional potential biomarkers, and why combination immunotherapy in renal cell carcinoma is still a work in progress.

OPTiM Follow-up Shows Improved CR Rate With T-VEC in Melanoma

March 7th 2016

Robert Andtbacka, MD, explains the goals of the retrospective analysis of the OPTiM study, the significance of its results, and the future for T-VEC in melanoma.

Expert Shares Challenges, Considerations When Using Immunotherapies in Melanoma

March 7th 2016

Michael Postow, MD, discusses the benefits and challenges of combination regimens versus single-agent regimens, the possibility of targeted agents with immunotherapies, and the management of toxicities with immunotherapies.

Will Immunotherapy or Targeted Therapy Take the Lead in Melanoma?

March 5th 2016

Michael Atkins, MD, discusses his views on the potential of immunotherapy versus targeted therapy in melanoma, what research has shown so far, and what could be on horizon for both classes of drugs going forward.

Beyond BRAF: Emerging Agents Aim at Other Melanoma Targets

March 2nd 2016

Jason Luke, MD, discusses how molecular subtyping has expanded targeted therapy approaches beyond BRAF inhibition, current trials investigating emerging targeted agents, and what can be expected in this space going forward.

Weber Compares BRAF/MEK, Immunotherapy Combos in Melanoma

March 1st 2016

Jeffrey S. Weber, MD, PhD, discusses recent long-term follow-up data of dabrafenib and trametinib in melanoma that may shed some light on sequencing questions for BRAF-mutated patients.

Lipids, Inflammation Linked to Multiple Myeloma Origins

March 1st 2016

Madhav Dhodapkar, MBBS, discusses research showing that nflammation and chronic stimulation of the immune system by lipids may trigger multiple myeloma in approximately one-third of all cases.

Neoadjuvant Treatment Now Mainstay in HER2+ Breast Cancer

February 29th 2016

Sunil Verma, MD, discusses emerging key agents in the neoadjuvant setting, advantages of treating prior to surgery, and questions that still remain regarding HER2-positive neoadjuvant therapy.

Novel Checkpoints Offer Hope After Standard Melanoma Immunotherapies Fail

February 29th 2016

Omid Hamid, MD, discusses promising agents and combinations that offer hope to patients with melanoma for whom standard checkpoint agents and/or targeted therapies are not an option.

Advances on the Horizon for ER+/HER2+ Breast Cancer, But Questions Remain

February 26th 2016

Sunil Verma, MD, discusses advancing treatment in ER+/HER2+ breast cancer, specific therapies that should be considered for this subgroup, upcoming clinical trials, and the biggest challenges and questions that remain in this setting.

Blackwell on Recent Advances in HER2-Positive Breast Cancer

February 25th 2016

Kimberly L. Blackwell, MD, discusses recent studies examining emerging agents in HER2-positive breast cancer.

Kipps on Impact of Potential Venetoclax Approval and Other Novel CLL Agents

February 25th 2016

Thomas Kipps, MD, PhD, provides insight on the potential impact of an FDA approval for venetoclax, the management of tumor lysis syndrome associated with venetoclax, and combination possibilities for the agent.

NEXT PAGE
PREVIOUS PAGE